

AMICUS THERAPEUTICS INC

Reported by
CROWLEY JOHN F

FORM 4/A

(Amended Statement of Changes in Beneficial Ownership)

Filed 10/20/17 for the Period Ending 10/12/17

Address	1 CEDAR BROOK DRIVE CRANBURY, NJ, 08512
Telephone	(609) 662-2000
CIK	0001178879
Symbol	FOLD
SIC Code	2834 - Pharmaceutical Preparations
Industry	Pharmaceuticals
Sector	Healthcare
Fiscal Year	12/31

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

[] Check this box if no longer
subject to Section 16. Form 4 or
Form 5 obligations may
continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or
Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *		2. Issuer Name and Ticker or Trading Symbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)	
Crowley John F		AMICUS THERAPEUTICS INC [FOLD]		<input checked="" type="checkbox"/> Director _____ 10% Owner	
(Last) (First) (Middle)		3. Date of Earliest Transaction (MM/DD/YYYY)		<input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below)	
C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE		10/12/2017		Chairman & CEO	
(Street)		4. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line)	
CRANBURY, NJ 08512		10/17/2017		<input checked="" type="checkbox"/> Form filed by One Reporting Person	
(City) (State) (Zip)				<input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)			
Common Stock	10/12/2017		M (1)		380000	A	\$14.2495 (2)	708001	D
Common Stock	10/12/2017		S (1)		380000	D	\$14.2495 (3)	328001	D
Common Stock	10/13/2017		M (1)		22160	A	\$14.7503 (4)	350161	D
Common Stock	10/13/2017		S (1)		22160	D	\$14.7503 (5)	328001	D
Common Stock	10/16/2017		M (1)		47135	A	\$14.75	375136	D
Common Stock	10/16/2017		S (1)		47135	D	\$14.75	328001	D
Common Stock								64895	D

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (right to buy)	\$6.45	10/12/2017		M (1)		5783		2/15/2016	2/15/2022	Common Stock	5783	\$0.00	131024	D	
Stock Options (right to buy)	\$4.38	10/12/2017		M (1)		13622		6/4/2016	6/4/2022	Common Stock	13622	\$0.00	136378	D	
Stock Options (right to buy)	\$3.53	10/12/2017		M (1)		3462		1/28/2017	1/28/2023	Common Stock	3462	\$0.00	161538	D	
Stock Options (right to buy)	\$2.52	10/12/2017		M (1)		165000		6/18/2017	6/18/2023	Common Stock	165000	\$0.00	0	D	
Stock Options (right to buy)	\$3.19	10/12/2017		M (1)		192133		1/3/2015	1/3/2024	Common Stock	192133	\$0.00	20972	D	
Stock Options (right to buy)	\$3.53	10/13/2017		M (1)		22160		1/28/2017	1/28/2023	Common Stock	22160	\$0.00	139378	D	
Stock Options (right to buy)	\$3.53	10/16/2017		M (1)		47135		1/28/2017	1/28/2023	Common Stock	47135	\$0.00	92243	D	

Explanation of Responses:

- (1) The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
- (2) This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from \$14.09 to \$14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- (3) This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from \$14.09

to \$14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

- (4) This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from \$14.75 to \$14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- (5) This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from \$14.75 to \$14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:
 This Form 4 amendment corrects the reporting person's Remarks from the originally filed Form 4. The Remarks should read as follows: Shares were sold to fund the "Megan K. Crowley 2016 Special Needs Trust", a trust for the benefit of Mr. Crowley's child, with the balance of the proceeds used for general estate planning purposes. The total shares sold represented less than 14% of Mr. Crowley's holdings of securities of the company and after these transactions, Mr. Crowley's percentage of shares beneficially owned is 1% of the company's outstanding shares.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Crowley John F C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE CRANBURY, NJ 08512	X		Chairman & CEO	

Signatures

/s/ John F. Crowley

10/20/2017

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.